Straits Times Index
3,328.90 -1.19 (-0.04%) Nikkei
38,556.87 -298.50 (-0.77%) Hang Seng
18,477.01 -344.15 (-1.83%) FTSE 100
8,237.98 -16.20 (-0.20%) Bitcoin USD
67,743.91 -211.79 (-0.31%) CMC Crypto 200
1,458.87 -25.83 (-1.74%)
RYTM Jan 2025 50.000 call
| Previous close | 5.50 |
| Open | 5.30 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.30 - 5.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 223 |
Simply Wall St.While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week
It hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...
GlobeNewswireRhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that re
- GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees. These inducement RSUs are subjec
